Statistical consideration for clinical biomarker research in bladder cancer
- 31 August 2010
- journal article
- review article
- Published by Elsevier BV in Urologic Oncology
- Vol. 28 (4), 389-400
- https://doi.org/10.1016/j.urolonc.2010.02.011
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Assessing the Performance of Prediction ModelsEpidemiology, 2010
- Clinical benefits of a multivariate prediction model for bladder cancerCancer, 2009
- Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit AllJournal of Biopharmaceutical Statistics, 2009
- Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markersBMC Medical Informatics and Decision Making, 2008
- Systematic review of statistical methods used in molecular marker studies in cancerCancer, 2008
- Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcomeHuman Pathology, 2007
- Method for evaluating prediction models that apply the results of randomized trials to individual patientsTrials, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Decision Curve Analysis: A Novel Method for Evaluating Prediction ModelsMedical Decision Making, 2006
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001